Research at University Health Network
Technology Transfer
Menu Level 3  
  Find a ...

 centre or program

  Quick Links
   Read research news
 View maps & directions
 Start a career with us
 Good Clinical Research Practice: Principles e-learning program
 Clinical Research Quality
 Office of Research Trainees
 CAPCR website

  Remote Tools & Access
   Staff Remote Access
 Research Webmail
 SecureDoc Viewers
 CAPCR Remote Login

Subscribe to UHN Research's RSS feed:


Ontario Cancer Institute Toronto General Research Institute Toronto Rehabilitation Institute Toronto Western Research Institute
  • Located at the Princess Margaret Cancer Centre, Toronto, Ontario
  • Research foci: cancer— genomics, informatics, molecular biology, clinical trials, signalling pathways, structural biology and biophysics.
  • 361 scientists and clinician-scientists
  • $162M external funding
  • more
  • Located at the Toronto General Hospital, Toronto, Ontario
  • Research foci: cardiology, transplantation, immunology and infectious disease
  • 230 scientists and clinician-scientists
  • $73M external funding
  • more
  • Located at Toronto Rehab, Toronto, Ontario
  • Research foci: rehabilitation sciences, cardiopulmonary fitness and mobility
  • 119 scientists and clinician-scientists
  • $8M external funding
  • more
  • Located at the Toronto Western Hospital, Toronto, Ontario
  • Research foci: Neural and visual sciences, musculoskeletal disease and community and population health
  • 159 scientists and clinician-scientists
  • $35M external funding
  • more


Royal Society of Canada Honours Dr. Fehlings
Sep 29, 2014

TWRI Senior Scientist Dr. Michael Fehlings was recently elected as Fellow to the Royal Society of Canada (RSC) for his outstanding contributions towards the development of translational therapeutics for spinal cord and brain injuries.

Election to the RSC is one of the highest honours a scholar can receive and recognizes the exceptional contributions that the recipient has made to their respective field.

The honour will be bestowed to Dr. Fehlings on Saturday, November 22, 2014 at the Fairmont Le Château Frontenac in Quebec City.

Full Story

Dr. Michael Tymianski's stroke drug receives $10 million grant
Sep 24, 2014

Stroke is one of the leading causes of death and disability world-wide. Dr. Tymianski, Head of Neurosurgery at TWH and Senior Scientist at TWRI, has dedicated two decades of his career to stroke research. Through this work, he has developed a promising new drug, NA-1, that may limit damage after stroke.

On Friday September 12th 2014, Brain Canada announced that it will provide $10 million to carry out a Phase III trial (the FRONTIER trial) that aims to test the ability of NA-1 to reduce tissue damage after stroke. As part of this trial, paramedics will administer the drug to 518 stroke patients in Toronto, Peel Region and Vancouver starting January 2015.

Previously, a Phase II trial for NA-1 (the ENACT trial) was carried out in collaboration with Dr. Michael Hill and colleagues at the University of Calgary in Alberta. The results, published in The Lancet Neurology, showed the safety and efficacy of the drug at reducing the number of new strokes in patients undergoing an endovascular repair procedure.

Full Story

September McEwen Monthly
Sep 22, 2014

The September issue of the McEwen Monthly is now available online! Read about a new study by Dr. Peter Zandstra, which uses a sophisticated approach to decipher how cells regulate blood development.

Also featured are stories on a new compound that could increase the number of stem cells for use in treating blood diseases and the election of three McEwen Centre Researchers to the Royal Society of Canada.

To read these stories and more, click here.

Full Story


Home Researchers Facilities Support Services Programs Commercialization Ethics News About UHN Institutes OCI Techna TGRI TRI TWRI